Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402

BACKGROUND: The tumor associated antigen (TAA) gp100 was one of the first identified and has been used in clinical trials to treat melanoma patients. However, the gp100 epitope peptide restricted to HLA-A*2402 has not been extensively examined clinically due to the ethnic variations. Since it is the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baba, Toshiyuki, Sato-Matsushita, Marimo, Kanamoto, Akira, Itoh, Akihiko, Oyaizu, Naoki, Inoue, Yusuke, Kawakami, Yutaka, Tahara, Hideaki
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2010
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2949666/
https://ncbi.nlm.nih.gov/pubmed/20843377
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-84
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados